{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.7","upperLimit":"31","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Acute GVHD is assessed using Consensus Criteria:\n\nOrgan Classifications:\n\n* 0: No rash due to GVHD; Bilirubin \\< 2 mg/dL; \\< 500 mL diarrhea/ day\n* 1: Maculopapular rash \\< 25% of body surface; Bilirubin 2-3 mg/dL; 500 to 999 mL diarrhea/ day or persistent nausea with histologic evidence of GVHD in stomach/ duodenum\n* 2: Maculopapular rash 25-50% of body surface; Bilirubin 3.1-6 mg/dL; 1,000 to 1,499 mL diarrhea/ day\n* 3: Maculopapular rash \\> 50% of body surface; Bilirubin 6.1-15 mg/dL; 1,500 or more mL diarrhea/ day\n* 4: Generalized erythroderma with bullous formation; Bilirubin \\> 15 mg/dL; Severe abdominal pain with or without ileus\n\nOverall Clinical Grade:\n\n* 0: No Stage 1-4 of any organ\n* I: Stage 1-2 rash and no liver or gut involvement\n* II: Stage 3 rash, or Stage 1 liver involvement, or Stage 1 gut involvement\n* III: None to Stage 3 skin rash with Stage 2-3 liver involvement, or Stage 2-4 gut involvement\n* IV: Stage 4 skin rash, or Stage 4 liver involvement","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients receive same therapy\n\nFludarabine: 30 mg/m2/day IV x 6 days\n\nMelphalan: 100 mg/m2/day IV x 1 day\n\nTotal Body Radiation: 200 cGy on Day 0\n\nCord Blood: 2 cord blood units IV","id":"OG000","title":"Fludarabine/Melphalan/TBI"}],"paramType":"NUMBER","populationDescription":"The two participants found to be ineligible after being consented and registered were excluded from the analysis.","reportingStatus":"POSTED","timeFrame":"100 Days","title":"Rates of Grade II-IV and Grade III-IV Acute Graft Versus Host Disease (GVHD) at 100 Days","type":"SECONDARY","unitOfMeasure":"percentage of participants"}